Zusammenfassung
Calciumantagonisten hemmen am Herzen und an der glatten Muskulatur den Einstrom von Calciumionen aus dem Extrazellulärraum. Dies führt zu einer Vasodilatation (vorwiegend der arteriellen Gefäße) und am Herzen zu einer Abnahme von Kontraktionskraft und Herzfrequenz, die allerdings durch eine adrenerge Gegenregulation infolge der Vasodilatation kompensiert wird.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Arzneimittelkommission der deutschen Ärzteschaft (1997): Calciumantagonisten vom 1,4-Dihydropyridin-Typ. Dtsch Ärztebl 22: C-1122-C-1123.
Cohn JN, Ziesche SM, Loss LE, Anderson GF, V-HeFT Study Group (1995): Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure: Results of V-HeFT VIII. Circulation 92: 1-143.
Dahlöf f, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators (2005): Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial- Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 366: 895-906.
Deutsche Gesellschaft für Kardiologie (2003): Leitlinien zur Behandlung der chronischen koronaren Herzkrankheit. Z Kardiol 92: 501-521.
Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, Hlatky MA (1999): Meta-analysis of trials comparing b-blockers, calcium antagonists, and nitrates for stable angina. JAMA 281: 1927-1936.
Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P (2009): Results of a meta- analysis comparing the tolerability of lercanidipine and other dihydropyridine cal- cium channel blockers. Clin Ther 31: 1652-1663.
Nationale Versorgungsleitlinie Chronische KHK. September 2006. Internet: http://www. versorgungsleitlinien.de/themen/khk/pdf/nvl_khk_kurz.pdf
Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ; CAMELOT Investigators (2004): Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292: 2217-2225.
Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE et al (1996): Effect of amlodi- pine on morbidity and mortality in severe chronic heart failure. N Engl J Med 335: 1107-1114.
Rothwell PM, Howard SC, Dolan E, O'Brian E, Dobson JE, Dahlöf B, Poulter NR, Sever PS ; ASCOT-BPLA and MRC Trial Investigators (2010): Effects of ß; blockers and calcium channel blockers on within-individual variability and risk of stroke. Lancet Neurol 9: 469-480.
Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG et al (1997): Randomised doubleblind comparison of placebo and active treatment for older patients with isolated sys- tolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350: 757-764.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002): The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981-2997.
The DEFIANT-II Research Group (1997): Doppler flow and echocardiography in functional cardiac insufficiency: assessment of nisoldipine therapy. Results of the DEFIANT-II Study. Eur Heart J 18: 31-40.
Tuomilehto J, Rastenyte D, Birkenhäger WH, Thjs L, Antikainen R et al (1999): Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 340: 677-684.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Medizin Verlag Berlin, Heidelberg
About this chapter
Cite this chapter
Eschenhagen, T. (2012). Calciumantagonisten. In: Arzneiverordnungs-Report 2012. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-29242-2_20
Download citation
DOI: https://doi.org/10.1007/978-3-642-29242-2_20
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-29241-5
Online ISBN: 978-3-642-29242-2
eBook Packages: Medicine (German Language)